What is Retatrutide?
Retatrutide is an investigational triple-hormone receptor agonist medication that targets GLP-1, GIP, and glucagon receptors, currently in Phase 3 clinical trials for obesity and related conditions, and is not yet FDA-approved or available as a prescription medication. 1, 2
Mechanism of Action
Retatrutide (LY3437943) is a novel synthetic molecule that simultaneously activates three distinct receptor pathways 2, 3:
- Glucagon-like peptide-1 (GLP-1) receptor - enhances insulin secretion and reduces appetite
- Glucose-dependent insulinotropic polypeptide (GIP) receptor - improves insulin sensitivity and metabolic function
- Glucagon receptor - increases energy expenditure and fat metabolism
This triple-agonist approach represents a paradigm shift beyond current GLP-1 and dual GIP/GLP-1 receptor agonists, offering a more comprehensive metabolic intervention 3.
Clinical Trial Evidence
Weight Loss Efficacy
The Phase 2 trial (NCT04881760) demonstrated unprecedented weight reductions in adults with obesity 2:
- At 24 weeks: 17.5% weight loss with 12 mg dose (vs. 1.6% with placebo)
- At 48 weeks: 24.2% weight loss with 12 mg dose (vs. 2.1% with placebo)
- 83% of participants on 12 mg achieved ≥15% weight loss at 48 weeks (vs. 2% with placebo) 2
These results are comparable to bariatric surgery outcomes and exceed those of currently approved medications 3.
Additional Metabolic Benefits
Beyond weight loss, retatrutide demonstrated significant improvements in metabolic dysfunction-associated steatotic liver disease (MASLD) 4:
- 82.4% reduction in liver fat at 24 weeks with 12 mg dose
- 86% of participants achieved normal liver fat (<5%) with 12 mg dose
- Improvements correlated with enhanced insulin sensitivity and lipid metabolism 4
Current Regulatory Status
Retatrutide is NOT currently FDA-approved and is NOT available as a prescription medication 1. The drug is undergoing Phase 3 clinical trials through the TRIUMPH program, which includes 5:
- TRIUMPH-1 and TRIUMPH-2: Weight management basket trials with nested OSA and knee osteoarthritis protocols
- TRIUMPH-3: Weight management in patients with cardiovascular disease
- TRIUMPH-4: Stand-alone knee osteoarthritis trial
- Total enrollment: Over 5,800 participants across all trials 5
The Phase 3 trials began in August 2023, and results are pending 6.
Safety Profile from Phase 2 Trials
The most common adverse events were gastrointestinal and dose-related 2:
- Nausea, vomiting, diarrhea (mostly mild to moderate severity)
- Starting with a lower initial dose (2 mg vs. 4 mg) partially mitigated GI side effects 2
- Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter 2
Important Caveat
While the Phase 2 data are promising, comprehensive long-term safety data are not yet available, and the drug has not undergone the full regulatory review process required for FDA approval 6.
Clinical Context
Retatrutide is being developed to address the limitations of current obesity pharmacotherapy, including GLP-1 receptor agonists like semaglutide (Wegovy) and dual agonists like tirzepatide 3. The triple-agonist mechanism may offer superior weight loss and metabolic benefits, but patients seeking obesity treatment should currently rely on FDA-approved medications such as semaglutide 2.4 mg, tirzepatide, or other approved agents 7.
Bottom Line for Clinical Practice
Retatrutide cannot be prescribed at this time - it remains an investigational agent undergoing Phase 3 trials 1, 5. Healthcare providers should continue using FDA-approved weight management medications while monitoring the progress of retatrutide through the regulatory approval process 7. If approved, retatrutide may represent a significant advancement in obesity pharmacotherapy, potentially offering weight loss comparable to bariatric surgery 3.